Cargando…

Development and Characterization of a Genetic Mouse Model of KRAS Mutated Colorectal Cancer

Patients with KRAS mutated colorectal cancer (CRC) represent a cohort with unmet medical needs, with limited options of FDA-approved therapies. Representing 40–45% of all CRC patients, they are considered ineligible to receive anti-EGFR monoclonal antibodies that have added a significant therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maitra, Radhashree, Thavornwatanayong, Thongthai, Venkatesh, Madhu Kumar, Chandy, Carol, Vachss, Dov, Augustine, Titto, Guzik, Hillary, Koba, Wade, Liu, Qiang, Goel, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888417/ https://www.ncbi.nlm.nih.gov/pubmed/31766149 http://dx.doi.org/10.3390/ijms20225677

Ejemplares similares

Toll-like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer
por: Maitra, Radhashree, et al.
Publicado: (2017)

Immune characterization of metastatic colorectal cancer patients post reovirus administration
por: Parakrama, Ruwan, et al.
Publicado: (2020)

Telomere length regulation through epidermal growth factor receptor signaling in cancer
por: Augustine, Titto, et al.
Publicado: (2017)

Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan
por: Maitra, Radhashree, et al.
Publicado: (2014)

Therapeutic Targets of KRAS in Colorectal Cancer
por: Rahman, Shafia, et al.
Publicado: (2021)

Noncoding RNA Profile in Reovirus Treated KRAS-Mutated Colorectal Cancer Patients
por: Saperstein, Rafael, et al.
Publicado: (2023)

Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer
por: Augustine, Titto, et al.
Publicado: (2022)

Immunotherapeutic advances in gastrointestinal malignancies
por: Rao, Devika, et al.
Publicado: (2019)

Transcriptome Signature of Immune Cells Post Reovirus Treatment in KRAS Mutated Colorectal Cancer
por: Fogel, Elisha J, et al.
Publicado: (2021)

Protein Arginine Methyltransferase 5 as a Therapeutic Target for KRAS Mutated Colorectal Cancer
por: Shifteh, David, et al.
Publicado: (2020)

Molecular Tools for Metastatic Colorectal Cancer Characterization
por: Maitra, Radhashree, et al.
Publicado: (2020)

Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin
por: Rao, Devika, et al.
Publicado: (2019)

Riluzole: A neuroprotective drug with potential as a novel anti-cancer agent (Review)
por: Blyufer, Angelina, et al.
Publicado: (2021)

The Synergistic Role of Diet and Exercise in the Prevention, Pathogenesis, and Management of Ulcerative Colitis: An Underlying Metabolic Mechanism
por: Stavsky, Jonah, et al.
Publicado: (2019)

A WW-like module in the RAG1 N-terminal domain contributes to previously unidentified protein–protein interactions
por: Maitra, Radhashree, et al.
Publicado: (2009)

Targeting Estrogens and Various Estrogen-Related Receptors against Non-Small Cell Lung Cancers: A Perspective
por: Maitra, Radhashree, et al.
Publicado: (2021)

BRG1: Promoter or Suppressor of Cancer? The Outcome of BRG1’s Interaction with Specific Cellular Pathways
por: Shaykevich, Aaron, et al.
Publicado: (2023)

Bajos fondos
por: Vachss, Andrew H.
Publicado: (1989)

Dead and gone/
por: Vachss, Andrew H.
Publicado: (2000)

Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer
por: Augustine, T A, et al.
Publicado: (2015)

Immunogenecity of Modified Alkane Polymers Is Mediated through TLR1/2 Activation
por: Maitra, Radhashree, et al.
Publicado: (2008)

COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19
por: Sapir, Tzuriel, et al.
Publicado: (2022)

Divergent immune landscapes of primary and syngeneic Kras-driven mouse tumor models
por: Gutierrez, Wade R., et al.
Publicado: (2021)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Impact of KRAS Mutations on Management of Colorectal Carcinoma
por: Sullivan, Kevin M., et al.
Publicado: (2011)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

KRAS Transitions and Villous Growth in Colorectal Adenomas
por: Risio, Mauro, et al.
Publicado: (2005)

KRAS-associated microRNAs in colorectal cancer
por: Ibrahim, Hamizah, et al.
Publicado: (2020)

KRAS mutations in patients with colorectal cancer in Libya
por: Abudabous, Asma, et al.
Publicado: (2021)

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
por: Tria, Simon Manuel, et al.
Publicado: (2023)

Mouse models of Kras activation in gastric cancer
por: Won, Yoonkyung, et al.
Publicado: (2022)

KRAS mutational analysis for colorectal cancer: Application: Pharmacogenomic
por: Wang, Grace, et al.
Publicado: (2010)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
por: Arrington, Amanda K., et al.
Publicado: (2012)

Novel KRAS Gene Mutations in Sporadic Colorectal Cancer
por: Naser, Walid M., et al.
Publicado: (2014)

Personalized treatment for advanced colorectal cancer: KRAS and beyond
por: Patel, Gargi Surendra, et al.
Publicado: (2013)

IMPACT OF KRAS MUTATIONS IN CLINICAL FEATURES IN COLORECTAL CANCER
por: ZANATTO, Renato Morato, et al.
Publicado: (2020)

Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
por: Koulouridi, Asimina, et al.
Publicado: (2022)

Mapping the KRAS proteoform landscape in colorectal cancer identifies truncated KRAS4B that decreases MAPK signaling
por: Adams, Lauren M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o49r508rfmaijq2nbmtfb97ulf